A randomized phase 2 study of irinotecan plus cetuximab with or without enzastaurin in patients with recurrent colorectal cancer.
Phase of Trial: Phase II
Latest Information Update: 30 Jun 2010
At a glance
- Drugs Cetuximab; Enzastaurin; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 30 Jun 2010 Results presented at 12th World Congress on Gastrointestinal Cancer 2010.
- 26 May 2009 Actual patient number (26) and actual end date (1 May 2009) added as reported by ClinicalTrials.gov.
- 26 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History